Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?

I would not use Toci prophylactically. I see more problems with ICANS/confusion in MM bispecifics, and this responds to steroids, not Toci, or resolves on its own.